Respiratory Antiviral Treatment Market Size to Hit US$ 5.4 Billion by 2030

According to latest report, the global respiratory antiviral treatment market size was reached at US$ 3 Bn in 2020 and is predicted to hit US$ 5.4 billion by 2030.

Respiratory Antiviral Treatment Market growth is expanding at a CAGR of 6.1% from 2021 to 2030. The growth of the global respiratory antiviral treatment market can be ascribed to rise in prevalence of respiratory viral diseases and ongoing clinical trials, and increase in FDA approvals.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38192

Antiviral drugs are therapeutics that prevent the development and replication of virus without affecting host cells. These drugs do not destroy their target virus, as it is an obligatory intracellular parasite. Instead, these inhibit their propagation by deactivating the viral enzymes. Different types of drugs are used in the treatment of respiratory viral diseases including ribavirin, aciclovir, oseltamivir, zanamivir amantadine, and amantadine.

Outbreak of Pandemic Respiratory Viral Diseases, Ongoing Clinical Trials, and Increase in FDA Approvals to Drive Global Market

The rise in prevalence and incidence of respiratory viral diseases such as influenza and bronchiolitis across the globe is a key factor driving the global respiratory antiviral treatment market. The WHO estimated that around 3 million to 5 million influenza cases occur globally every year; 250,000 to 500,000 of these result in deaths. Hence, increase in incidence of influenza continues to encourage the use of influenza medication, thereby driving the market. According to the CDC, COVID-19 pandemic resulted in over 814,000 deaths globally, as of August 2020.

Ongoing clinical trials for respiratory viral disease treatment, drugs, pipeline products, and safety and efficacy studies have increased over the past few years. Moreover, marketing approvals for antiviral therapies and drugs by the FDA and other authorities in different regions are expected to boost the growth of the global respiratory antiviral treatment market. In October 2019, Genentech, Inc. received the U.S. Food and Drug Administration (FDA) approved for Xofluza (Baloxavir Marboxil) for people at high risk of developing influenza-related complications.

Scope of The Report

Healthcare Facilities Increase Influenza and COVID-19 Testing Due to Ongoing Flu Season

The coronavirus (COVID-19) outbreak has sparked concern among individuals suffering from influenza. Due to similarities in symptoms, healthcare institutes are increasing awareness about the differences in symptoms. Though influenza and COVID-19 are both contagious respiratory illnesses, they are caused by different viruses. This confusion has created revenue opportunities for companies in the respiratory antiviral treatment market, since infected individuals are seeking professional help from doctors to identify the symptoms.

Influenza is a serious medical issue in western countries. A second wave of COVID-19 in European countries is likely to compromise healthcare facilities. Hence, healthcare professionals are identifying people at high risk of acquiring influenza and COVID-19, and are recommending preventive measures to minimize the pressure in healthcare facilities.

RSV-associated Clinical Trails Holds Promising Potentials for Development of Bronchiolitis Antivirals

Innovations in the treatment of respiratory syncytial virus (RSV) infection hold promising potentials for the bronchiolitis treatment. For instance, Ark Biosciences— a biotech company specializing in therapeutics for viral infections and respiratory illnesses has announced a successful completion of the phase 2 proof-of-concept study for Ziresovir (AK0529), which is an antiviral agent. Bronchiolitis has led to several hundreds of thousands of deaths worldwide, especially of children under five years of age. Hence, companies in the respiratory antiviral treatment market are increasing their research capabilities to develop therapeutics for bronchiolitis in infants.

Current antiviral agents developed by companies in the respiratory antiviral treatment market are found to have clinical benefits but are not licensed by healthcare institutions. Companies are increasing efforts to develop antivirals that are effective in reducing signs and symptoms of bronchiolitis in infants.

Antiviral Therapies Emerge as Alternative to Influenza Vaccines in High-risk Patients

The antiviral treatment is being highly preferred to shorten the duration of influenza symptoms. Moreover, these antivirals help to decrease the length of hospitals stays and minimizes the risk of complications in patients. As suggested by the CDC (Centers for Disease Control and Prevention), antiviral therapies help to improve medical outcomes in high-risk patients. As such, antiviral chemoprophylaxis is gaining increased popularity for influenza prevention and is being used as an adjunct to vaccination. Companies in the respiratory antiviral treatment market are boosting their output capacity to produce antiviral chemoprophylaxis meant for high-risk patients who cannot receive vaccination due to medical reasons.

Since high-risk patients such as pregnant women are susceptible to contraindications by vaccines, companies in the respiratory antiviral treatment market are increasing awareness about antiviral chemoprophylaxis to treat influenza. Patients with insufficient immune response are also recommended with antiviral chemoprophylaxis.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38192

Report Highlights

• In terms of drug class, the global respiratory antiviral treatment market has been divided into nucleoside analogs, neuraminidase inhibitors, ion channel blockers, and fusion protein inhibitors. The neuraminidase inhibitors segment dominated the global respiratory antiviral treatment market in 2019. This trend is likely to continue during the forecast period. Oseltamivir is first-line treatment for several respiratory viral diseases such as influenza. It is available as a prodrug oseltamivir phosphate and is converted by the liver to active metabolite oseltamivir carboxylate. The mechanism of action of oseltamivir carboxylate and other NAIs is to interfere with the release of influenza viral particles from infected host cells by binding to influenza viral neuraminidase, resulting in reduced spread of influenza viruses in the respiratory tract. This factor is projected to drive the segment.
• Nucleoside analogs was the second largest segment in terms of market share in 2020. The growth of the segment can be attributed to increase in demand for nucleoside analogs, owing to rise in occurrence of seasonal influenza and RSV infection.
• In terms of disease type, the global respiratory antiviral treatment market has been categorized into influenza, bronchiolitis, pneumonia, upper respiratory tract infections (URTIs), and others (measles, etc.). The influenza segment accounted for prominent share of the global respiratory antiviral treatment market in 2020, owing to rise in number of patients and awareness about the disease. According to the World Health Organization, around 1 billion influenza cases are reported globally each year, and 300,000 to 500,000 deaths occur due to influenza in every year.
• In terms of distribution channel, the global respiratory antiviral treatment market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment led the global respiratory antiviral treatment market in terms of revenue in 2020. The trend is expected to continue during the forecast period. Rapid increase in the number of hospitals and wide range of services available in multispecialty hospitals are likely to augment the segment during the forecast period. The surge in the number of patients opting for retail pharmacies due to a large number of product brands available at discounted prices at these pharmacies is projected to drive the retail pharmacies segment during the forecast period.
• North America dominated the global respiratory antiviral treatment market in 2020, followed by Europe. North America’s large market share can be ascribed to increase in the number of people with respiratory viral diseases, new product launches, and presence of major players in the region. According to the CDC, around 5.6 million patients are suffering from COVID-19 in the U.S., as of August 2020.
• The respiratory antiviral treatment market in Asia Pacific is anticipated to expand at a high CAGR from 2021 to 2030. This can be ascribed to the presence of developing countries with commercial hubs, expanding business organizations, rise in awareness about respiratory antiviral, improving healthcare infrastructure, and increase in investments by companies in their technical aspects.

Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2017 to 2019.

The analysts have provided a comprehensive analysis of the competitive landscape of the global respiratory antiviral treatment market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation expected to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users) and other segments.

• Company Overview
• Company Market Share/Positioning Analysis
• Product Offerings
• Financial Performance
• Recent Initiatives
• Key Strategies Adopted by Players
• Vendor Landscape
• List of Suppliers
• List of Buyers

Key players operating in the global market include F. Hoffmann-La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company Limited, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Mylan, Inc., Merck & Co., Inc., and AstraZeneca plc.

Market Segmentation

By Drug Class

• Nucleoside Analogs
  • Ribavirin
  • Aciclovir
  • Others
• Neuraminidase Inhibitors
  • Oseltamivir
  • Zanamivir
  • Others
• Ion Channel Blockers
• Fusion Protein Inhibitors

By Disease Type

• Influenza
• Bronchiolitis
• Pneumonia
• Upper Respiratory Tract Infections (URTIs)
• Others (measles, etc.)

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38192

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://qyresearchmedical.com/